All IndicationsNeurology & CNSPhase 3Phase 3Phase 3Phase 3Phase 2
🧠
Migraine
4
Companies
6
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
IPN.PA
Ipsen
Dysport
AXSM
Axsome Therapeutics, Inc.
AXS-07
AXSM
Axsome Therapeutics, Inc.
AXS-07 (meloxicam-rizatriptan)
AXSM
Axsome Therapeutics, Inc.
AXS-07 (MoSEIC meloxicam and rizatriptan)
LLY
Eli Lilly and Company
LY3451838
ABBV
AbbVie
Qulipta
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| IPN.PA Ipsen | Dysport | Phase 3 | — | — | — |
| AXSM Axsome Therapeutics, Inc. | AXS-07 | Phase 3 | — | — | — |
| AXSM Axsome Therapeutics, Inc. | AXS-07 (meloxicam-rizatriptan) | Phase 3 | — | — | — |
| AXSM Axsome Therapeutics, Inc. | AXS-07 (MoSEIC meloxicam and rizatriptan) | Phase 3 | — | — | — |
| LLY Eli Lilly and Company | LY3451838 | Phase 2 | — | — | — |
| ABBV AbbVie | Qulipta | — | — | — | — |
Development Stage Distribution
Unknown
1
Phase 3
4
Phase 2
1
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not financial advice
Signals are probabilistic and based on historical data — past performance doesn't guarantee future results. Do your own research.